Astrana Health: A Compelling Growth Story with Strong Q1 Performance and Strategic Acquisition

William Blair analyst Ryan Daniels has maintained their bullish stance on ASTH stock, giving a Buy rating on April 23.

Ryan Daniels has given his Buy rating due to a combination of factors, including Astrana Health’s strong first-quarter performance and positive future outlook. Despite sales slightly missing expectations, the company exceeded adjusted EBITDA forecasts, indicating robust operational efficiency.
Furthermore, the management’s reaffirmation of the 2025 outlook, coupled with the anticipated benefits from the Prospect Health acquisition, strengthens the growth narrative. The acquisition, which has received regulatory approval, is expected to enhance Astrana’s long-term EBITDA growth potential. These elements collectively position Astrana Health as a compelling growth story within the healthcare services sector.

In another report released on April 23, Jefferies also maintained a Buy rating on the stock with a $44.00 price target.